

SPL/NSE/2012-13

February 14, 2013

National Stock Exchange of India Limited
"EXCHANGE PLAZA"
Bandra-Kurla Complex,
Bandra (E),
MUMBAI-400 051
Fax No. 022-2659 8237/38,
022-2659 8347/48

SCRIPT CODE: 532516

**Sub: COMPLIANCE OF THE LISTING AGREEMENT/OUTCOME OF THE
BOARD MEETING HELD ON 14TH FEBRUARY, 2013**

Dear Sir,


1. In compliance with Clause 41 of the Listing Agreement, please find enclosed un-audited Financial Results (Provisional) of the Company for the quarter ended December 31, 2012 which were taken on record by the Board of Directors of the Company in their meeting held on February 14, 2013.
2. In compliance with Clause 41 of the Listing Agreement, please find enclosed Limited Review Report on un-audited Financial Results (Provisional) of the Company for the quarter ended December 31, 2012 from the Statutory Auditors of the Company.
3. Further to inform you that Mr. Subhash Chander Marwaha has been appointed as Nominee Director – SBI w.e.f 23.01.2013.
4. Further In continuation of our previous communication with respect to decision of State Bank of India (the lead bank) for restructuring of the company's debt, it is hereby informed that the Corporate Debt Restructuring empowered group(CDR-EG) has approved the restructuring package and taken on record in the Board of Directors meeting held on 14th February , 2013

This is for your information and records please.

Thanking you,

Yours faithfully,

For **Surya Pharmaceutical Limited**



B.B. Jain

Company Secretary

Encl: As above

Surya Pharmaceutical Limited

Corporate Office : SCO 164-65, Sector 9-C, Madhya Marg, Chandigarh-160 009 (INDIA)
Tel : +91 172 5005000 FAX: +91 172 5076000 Email : info@suryapharma.com ; Website : www.suryapharma.com
Regd. Office : 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110 006 (INDIA)



SURYA PHARMACEUTICAL LIMITED

REGD. OFFICE: 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110 006 (INDIA)

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED DECEMBER 31, 2012

		Quarter ended			Nine Months Ended		Rs. In Lacs
Sr. No.	PART -I Particulars	31.12.2012 Unaudited	30.09.2012 Unaudited	31.12.2011 Unaudited	31.12.2012 Unaudited	31.12.2011 Unaudited	Year Ended 31.03.2012 Audited
1	Net Sales/Income from Operations(Net of Excise Duty)	1001.72	1,525.38	54983.50	5,651.56	142554.90	162,294.90
	Total	1001.72	1,525.38	54983.50	5,651.56	142554.90	162,294.90
2	Expenditure						
a.	(Increase)/Decrease in Stock in Trade and WIP ,FG	630.87	1,122.24	2134.42	(1,056.41)	(9541.28)	5,735.44
b.	Consumption of Raw Materials	690.65	1,624.13	40921.30	8,919.35	118692.50	159,715.37
c.	Purchase of Traded Goods	-	-	433.60	-	1119.5	-
d.	Employees' benefits expense	196.03	236.29	1380.57	847.72	3549.30	4,091.11
e.	Depreciation/Amortisation	1019.71	900.53	895.21	2,846.54	2556.90	3,461.74
f.	Other Expenditure	372.22	408.08	2671.80	1,972.30	6804.10	8,230.74
g.	Total	2,909.48	4,291.27	48,436.90	13,529.50	123,181.02	181,234.40
3	Profit from Operations before Other Income,	(1,907.76)	(2,765.89)	6,546.60	(7,877.94)	19,373.88	(18,939.50)
	Finance Costs & Exceptional Items (1-2)						
4	Other Operating Income	3.41	2.92	122.07	100.18	803.70	(3,798.13)
5	Profit before Finance Costs & Exceptional Items (3+4)	(1,904.35)	(2,762.97)	6,668.67	(7,777.76)	20,177.58	(22,737.63)
6	Finance Costs	5889.48	5,037.00	4498.89	16,597.36	12856.70	16,584.84
7	Profit after Finance Costs but before Exceptional Items (5-6)	(7,793.83)	(7,799.97)	2,169.77	(24,375.12)	7,320.88	(39,322.47)
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before tax (7+8)	(7,793.83)	(7,799.97)	2,169.77	(24,375.12)	7,320.88	(39,322.47)
10	Tax expenses-Current Tax & Deferred Tax	-	-	-	-	-	12,072.46
11	Net Profit from Ordinary Activities after tax (9-10)	(7,793.83)	(7,799.97)	2,169.77	(24,375.12)	7,320.88	(27,250.01)
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	(7,793.83)	(7,799.97)	2,169.77	(24,375.12)	7,320.88	(27,250.01)
14	Paid-up Equity Share Capital (Face Value of Rs.1/- per Share)	2027.52	2027.52	2027.52	2027.52	2027.52	2027.52
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	22,720.45
16	Earnings Per Share (EPS)						
a.	Basic and diluted EPS before Extraordinary items	(3.84)	(3.84)	1.07	(12.02)	3.61	(13.44)
b.	Basic and diluted EPS after Extraordinary items	(3.84)	(3.84)	1.07	(12.02)	3.61	(13.44)

NOTES:

- The above results have been reviewed by the Audit Committee on 13-02-2013 and taken on record by the Board of Directors at its meeting held on 14.02.2013
- The above results have undergone Limited Review by the Statutory Auditors of the Company.
- Provision for Deferred tax as per AS 22 will be made in the Audited Results.
- No Depreciation has been provided on block of assets related to jammu plant.
- The debt restructuring proposal of the company has been approved by corporate debt restructuring Empowered group(CDR EG) in its meeting held on 31-12-2012.
- Impairment in value of stocks, if any shall be considered in the audited accounts.
- The Company operates in only one segment.
- Figures have been regrouped/rearranged wherever considered necessary.

For and on behalf of Board of Directors
For Surya Pharmaceutical Limited

Rajiv Goyal

Rajiv Goyal

(Chairman & Managing Director)

Place: Chandigarh
Date: 14th Feb.2013

		Quarter ended			Year Ended
PART -II	Particulars	31.12.2012	30.09.2012	31.12.2011	31.03.2012
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of Shares	159713656	159713656	125488750	125488750
	- Percentage of Shareholding	78.77	78.77	61.89	61.89
2	Promoter and Promoter Group Shareholding:				
a)	Pledged/Encumbered				
	- No. of Shares	41869974	41869974	76094880	76094880
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	97.28	97.28	98.49	98.49
	- Percentage of Shares (as a % of the total share Capital of the Company)	20.65	20.65	37.53	37.53
b)	Non-Encumbered				
	- No. of Shares	1168750	1168750	1168750	1168750
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	2.72	2.72	1.51	1.51
	- Percentage of Shares (as a % of the total share Capital of the Company)	0.58	0.58	0.58	0.58
	Particulars	3 months ended 31/12/2012			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter	0			
	Received during the quarter	0			
	Disposed of during the quarter	0			
	Remaining unresolved at the end of the quarter	0			



**The Board of Directors
M/s. Surya Pharmaceutical Limited
Delhi**


We have reviewed the accompanying statement of unaudited financial results of M/S. SURYA PHARMACEUTICAL LIMITED for the period ended **31.12.2012** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: February 13, 2013
Place: Chandigarh

FOR AAD & ASSOCIATES
CHARTERED ACCOUNTANTS



SHAMSHER SINGH
PARTNER
M. NO. 83898